Extensive Neurolymphomatosis as the Sole Site of Relapse in Mantle Cell Lymphoma.

Clin Nucl MedSep 11, 2026 (epub)
Case ReportHematologyRadiology (Diagnostic)

Futao Cui, Yunyi Liu, Rong Tian et al.

✦ AI-curated · Sources linked

Case in brief

A 60-year-old man with mantle cell lymphoma developed acute neurological symptoms after achieving complete remission. 18F-FDG PET/CT and brain PET/MR showed multiple enlarged spinal roots or nerves with intense FDG uptake. The findings led to a final diagnosis of recurrent mantle cell lymphoma involving the nerves, with neurolymphomatosis as the sole site of relapse.

What made this case unusual

The relapse was confined to extensive neurolymphomatosis, an extremely rare association with mantle cell lymphoma.

Diagnostic / clinical pearl

In a patient with mantle cell lymphoma in remission who develops acute neurological symptoms, nerve or spinal-root enlargement with intense FDG uptake can indicate neurolymphomatosis.

Source

PubMed · PMID 42752524

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.